Taisho Pharmaceutical Co., Ltd.

Other

Mcw Research Foundation, Inc.

Kazuya Kameo

Fumie Sato

Naoya Ono

Tohru Tanami

Jun Goto

Takehiro Amano

Masaru Mutoh

Kazuyuki Tomisawa

Toru Matsunaga

Kaoru Sota

Shiuji Saito

Shigeru Okuyama

Kenji Yamada

Atsuro Nakazato

Toshihito Kumagai

Jiro Sawada

Yoshimoto Nakashima

Masato Takahashi

Masakazu Sato

Hiroshi Fukushima

Taketoshi Okubo

Kazunori Hanada

Richard J Roman

Noriyuki Miyata

Masami Goi

Masaharu Tamai

Kiyoshi Oguma

David R Harder

Akira Hiratate

Yasuhide Tachi

Taketoshi Okubu

Kaoru Sata

A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.

Use of 20-HETE synthesizing enzyme inhibitors as therapy for cerebral vascular disease

A benzenesulfonate salt of (2S,4S)-2-cyano-4-fluoro-1-[(2-hydroxy-1,1-dimethyl)ethylamino]acetylpyrrolidine that has an excellent DPPIV inhibition activity as well as physical properties (e.g., stability) required for pharmaceutical preparations. The present invention allows easy obtaining of the compound in high-purity uniform crystal form with excellent solid-state stability.

Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives

A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula [I]:A-Het [I]has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

Tetrahydropyridino or piperidino heterocyclic derivatives

A tetrahydropyridino or piperidino heterocyclic derivative represented by the formula [I]:A-Het &#x2003;&#x2003;[I]has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

Tetrahydropyridino or piperidino heterocylic derivatives

Sleep inducing agent

A prostaglandin derivative represented by the formula:

Prostagladin derivatives

Process for the preparation of E-prostaglandins

Prostaglandin E.sub.1 analogues

A prostaglandin derivative represented by the formula: ##STR1## wherein X is halogen atom R.sup.1 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and R.sup.2 is a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkylmethyl group having 4 to 10 carbon atoms or a cycloalkylethyl group having 5 to 12 carbon atoms, or a salt thereof, which has an excellent lowering action of intraocular pressure and improving actions of renal diseases, ischemic heart diseases and heart failure.

Prostaglandin derivatives

Benzoylpropionic acid derivatives represented by the general formula ##STR1## (wherein R.sup.1 represents a hydrogen atom, a lower alkyl group or a benzyl group, R.sup.2 represents a lower alkyl group or a phenyl group, X represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a phenoxy group or a halogenophenoxy group, and Y represents a hydrogen atom or a lower alkyl group). The compounds have immunomodulative function and are effective for treatment of diseases caused by abnormal immunofunction.

Benzoylpropionic acid derivatives

3-Benzoyl-2-mercaptopropionic acid derivatives represented by the general formula ##STR1## (wherein, X represents a hydrogen atom, a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group, Y represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, Z represents a hydrogen atom or an acyl group, and R represents a hydrogen atom or a lower alkyl group). These compounds have immunomodulative function and are effective for the treatment of diseases caused by abnormal immunofunction.

3-benzoyl-2-mercaptopropionic acid derivatives

Growing community of inventors

Tokyo, Japan

Kazuya Kameo